MAG treated with HER2-overexpressing ovarian cancer cells showed downregulation of HER2 mRNA expression mediated by the suppression of VEGF, MMP-2, cyclin-D1 proteins and the PI3K/AKT/mTOR-signaling pathway and enhancement in PARP cleavage and activated caspase-3 [149]. The gene discussed is ERBB2; the disease is ovarian cancer.